Intelligent Bio Solutions Partners with SMARTOX for Global SmarTest Patch Distribution

Intelligent Bio Solutions Inc. has partnered with SMARTOX to distribute its SmarTest Patch drug detection product internationally outside of the US and Canada. The partnership strengthens INBS's position as a global leader in non-invasive drug testing solutions, offering continuous sweat-based drug detection over an extended period. The SmarTest Patch opens new opportunities for INBS, particularly in the justice and rehabilitation markets.

Intelligent Bio Solutions Inc. (INBS) has announced a strategic partnership with SMARTOX to distribute its SmarTest Patch drug detection product internationally, outside of the US and Canada. This collaboration strengthens INBS's position as a global leader in non-invasive drug testing solutions, offering continuous sweat-based drug detection over an extended period. The SmarTest Patch, developed by SMARTOX, is a discreet, water-resistant, and tamper-evident device worn on the skin for 7 to 10 days, continuously collecting sweat to detect various substances such as cocaine, opiates, methamphetamines, marijuana, and fentanyl [1].

The addition of the SmarTest Patch to INBS's product portfolio complements its flagship product, the Intelligent Fingerprinting Drug Testing Solution, allowing the company to address both short-term and continuous detection needs. This new capability opens up significant opportunities in the justice and rehabilitation sectors, where longer detection windows are critical. The global drug testing market is projected to grow to approximately $18.6 billion by 2030, highlighting the potential for substantial growth in this area [2].

INBS currently delivers noninvasive drug testing solutions to over 450 active accounts in 24 countries, supporting clients in the health, justice, and workplace sectors. With the SmarTest Patch, the company can now offer a more flexible and complete solution to its international customers. The partnership with SMARTOX is part of INBS's broader U.S. expansion strategy, which includes prioritizing FDA clearance for its fingerprint sweat-based drug testing technology beyond Forensic Use Only settings [3].

The stock of INBS (NASDAQ: INBS) saw a 2.05% increase during the premarket session on Wednesday, trading at $1.94. This positive market reaction reflects investor confidence in the company's ability to leverage the SmarTest Patch to capture a larger share of the growing global drug testing market [1].

References:

[1] https://finance.yahoo.com/news/exclusive-intelligent-bio-targets-global-120302704.html
[2] https://www.benzinga.com/news/health-care/25/07/46439329/exclusive-intelligent-bio-targets-global-market-with-distribution-pact-for-sweat-based-drug-detection-patch
[3] https://www.morningstar.com/news/globe-newswire/9493971/intelligent-bio-solutions-adds-next-gen-wearable-for-extended-drug-detection-to-product-offering-strengthening-leadership-in-non-invasive-testing